Retrospective analysis of treatement modalities and treament outcome in young high-risk patients aged <70 years with diffuse large b-cell lymphoma at Freiburg University CCCF Lymphomacenter.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00009982

Enrollment

Registered

2016-02-02

Start date

2016-02-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C83.3

Interventions

Group 1: Retrospective analysis of all young high risk DLBCL (aaIPI 2-3) patients according to treatement modalities and outcome presented at Freiburg University Medical Center from 2005 to 2015. Grou

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Age 18 – 70. Primary DLBCL or grade 3b FL without clinical or radiological signs of CNS disease and cytology - CSF. aaIPI 2-3 and/or Site specific risk factors for CNS disease. First-line therapy at University Freiburg Lymphoma Center

Exclusion criteria

Exclusion criteria: Clinical or radiological signs of CNS disease. Positive CSF

Design outcomes

Primary

Measure	Time frame
Overall response rate, complete-remission rate.	—

Secondary

Measure	Time frame
Progression-free-, and overall-survival.	—

Countries

Germany

Contacts

Public ContactReinhard Marks

Medizinische Klinik I - LymphomzentrumUniversitätsklinikum Freiburg

reinhard.marks@uniklinik-freiburg.de0761/270-36190

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026